Regulatory Considerations for Coronary Drug-Coated Balloons - Tara Ryan

↳ This is a section part of Moment: CRT 2017 : DES BIOABSORBABLE & DCB TECHNOLOGIES - DCB Technology Symposium - Coronary

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$14.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Regulatory Considerations for Coronary Drug-Coated Balloons - Tara Ryan  at CRT 2017.

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$14.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Learning Objectives

Other Components in this Moment

Overview
DCB for In-Stent Restenosis: Is It Superior to DES? - Robert Byrne
Is There Any Role of DCB for the Treatment of De Novo Lesions? - Azeem Latib
DCB as Adjunct Therapy to DES and BRS - Azeem Latib
The Virtue Micropore Drug Eluting Balloon - Dean Kereiakes
Long-Term Survival Benefit of DCB Versus DES for ISR Despite Angiographic Disadvantage of DCB - Bruno Scheller
Sirolimus Eluting Drug-Coated Balloons - Bernardo Cortese
Regulatory Considerations for Coronary Drug-Coated Balloons - Tara Ryan
Loading Simple Education